Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc. is positioning itself positively in the biopharmaceutical sector with its innovative RNA editing drug, KRRO-121, which targets liver conditions by stabilizing glutamine synthetase and improving ammonia clearance, thus addressing significant unmet medical needs. The company has demonstrated promising preclinical data indicating that KRRO-121 could achieve approximately 40% editing on glutamine synthesis, potentially creating substantial market opportunities with an estimated pharmacoeconomic upside of $3.5 billion across its target indications. As Korro Bio prepares for an Investigational New Drug (IND) application and Phase 1 first-in-human study slated for the second half of 2026, the pipeline advancements and demonstrated safety profile are factors contributing to a positive outlook on the stock.

Bears say

Korro Bio's stock faces a negative outlook primarily due to the disappointing results from its KRRO-110 program, leading to a significant stock selloff, and the announcement of potential delays and risks associated with its pipeline candidates, particularly KRRO-121. There are ongoing concerns regarding the company's ability to generate favorable clinical data, which is crucial for market confidence, and potential regulatory disputes that could undermine the interpretation of clinical trial results. Furthermore, the threat of new treatment developments by competitors and possible intellectual property infringement suits could impose additional financial burdens and impact the viability of Korro Bio's therapies.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.